Clinical Trial

Integrin αvβ6-targeted PET in Malignant Tumors

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 30, 2025 (before its estimated November 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. Integrin αvβ6 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous or reconstructed epithelial cells. A new PET probe, 68Ga-Trivehexin, targeting integrin αvβ6 has been developed with better affinity and selectivity than previous probes. Clinical data supports its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of tumors, providing a new and precise evaluation method for malignant tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-04-18.
Trial Details
NCT Number NCT05835570
Lead Sponsor Zhongnan Hospital
Conditions Malignant Neoplasm, PET/CT, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic
Enrollment 200 participants
Start Date 2023-01-01
Primary Completion 2025-11-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-30